Genentech acquiring Versant-backed NASH play Jecure

Genentech Inc. is acquiring Jecure Therapeutics Inc. (San Diego, Calif.), giving it a preclinical program targeting NLR family pyrin domain containing 3 (NLRP3; NALP3; CIAS1) to treat inflammatory diseases including non-alcoholic steatohepatitis. Financial terms are undisclosed.

Jecure’s sole investor was Versant Ventures.

Read the full 417 word article

User Sign In